Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

Income Statement

Follow revenue through to earnings.

Revenue

$500,000.00

FY 2025 · Annual

Operating Income

-$38.26M

FY 2025 · Annual

Net Income

-$41.88M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

MREO Earnings Waterfall · TTM

NASDAQ:MREO · Revenue to Net Income

Key Ratios

EPS$-0.22
Gross Margin18.4%
Net Margin-730.8%
P/E Ratio-5.8
P/S Ratio216.6

Analysis

$500.0K of revenue converted into -$35.7M of net income for the selected period. Gross margin is 18.4% and net margin is -730.8%, showing how much revenue survives after costs and taxes. EPS is $-0.22, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportAug 19, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
10-QQuarterly reportAug 11, 2026
8-KCurrent reportAug 11, 2026
8-KCurrent reportAug 11, 2026

How much revenue does MREO generate?

Mereo BioPharma Group plc (MREO) reported $500,000.00 of revenue in fiscal 2025.

Is MREO profitable?

Mereo BioPharma Group plc (MREO) reported -$41.88M of net income, with a net margin of -8375.6%.